Cloudbreak gains on new drug's progress
08/12/2025 05:48
** Cloudbreak Pharma Inc 2592.HK gains 7.5% to HK$8.60; set for biggest one-day pct drop since November 28 ** Ophthalmic therapies developer's unit schedules to meet with U.S. FDA on Wednesday at End-of-Phase 2 meeting to discuss potential Phase 3 clinical trial development, New Drug Application requirements for CBT-004 - drug used to treat vascularised pinguecula ** Co says it considers meeting to be significant milestone in CBT-004's development ** Since market debut on July 3, stock falls 15.2% (Reporting by Donny Kwok) ((donny.kwok@thomsonreuters.com))
Recent news on Cloudbreak Pharma
See all newsHong Kong watchdog tells firms how to cooperate in raids as scrutiny of share sales grows
Hong Kong watchdog tells firms how to cooperate in raids as scrutiny of share sales grows
Brief: Cloudbreak Pharma Says FDA Completes Safety Review Of CBT-358 Ind Application With No Objection
Brief: Cloudbreak Pharma Enters Share Subscription Agreement With Arc Group International For Up To $15 Mln
Brief: Cloudbreak Pharma Announces Final Patient Visit for 12-Month Efficacy Endpoint in Phase 3 Study of CBT-001 as a Potential Treatment for Pterygium